As of 13 Nov 2026, Synphatec has raised $50M across 1 verified round on record; latest: over $50 million Series A led by Decheng Capital, announced 28 Sep 2026.
CNS Innovative Drug Developer
synphatec.comLinkedInShanghai, ChinaBiotechFounded 2021
3 sources · checked 33 times, last 2d ago
Source 1's summary omits Huatai GenScript Fund and Qianju Capital from its table; Source 2's explicit syndicate description is more specific and controls.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series A | $50M | 2026-09-28 | Decheng Capital | No recent discussion |
3 sources · checked 33 times, last 2d ago [ VERIFIED · CORRECTED ] read against 3 sources Source 1's summary omits Huatai GenScript Fund and Qianju Capital from its table; Source 2's explicit syndicate description is more specific and controls. | ||||
1 person on 2 outlets
Found on X with Firecrawl search
Synphatec is a neuroscience biotechnology company developing CNS medicines for psychiatric and neurodegenerative disorders, including depression and Alzheimer's disease.
Synphatec is pursuing CNS treatments for major unmet needs in depression and Alzheimer's disease, including a rapid-acting antidepressant aimed at improving on the safety limitations of existing NMDA-receptor therapy and a gene-therapy approach intended to inhibit beta-amyloid production at its source. Its latest Series A financing of over $50 million is earmarked for clinical development of SP-101 and SP-201, optimization of the i-NaS and SynX platforms, and expansion of its innovative pipeline.
Checked against 8 sources on Sep 28